RGS20 Antibody
Description
Introduction to RGS20 Antibody
RGS20 antibodies are immunological reagents designed to target the RGS20 protein, which belongs to the RZ family of GTPase-activating proteins (GAPs). These antibodies are widely used in techniques such as Western blot (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA) to study RGS20's expression and function in normal and pathological tissues .
Renal Cell Carcinoma (RCC)
-
Expression: RGS20 mRNA and protein levels are elevated in RCC tissues and cell lines (e.g., A-498, 786-O) compared to normal renal cells .
-
Prognostic Value: High RGS20 correlates with advanced TNM stage, lymph node metastasis, and poor survival .
-
Functional Impact: Knockdown of RGS20 in A-498 cells reduces proliferation, migration, and invasion while increasing apoptosis .
Penile Cancer (PC)
-
Oncogenic Role: RGS20 overexpression promotes cell viability, migration, and tumor growth via PI3K/AKT signaling. Depletion suppresses these effects in xenograft models .
-
Clinical Relevance: High RGS20 expression is linked to pelvic metastasis and shorter progression-free survival .
Non-Small Cell Lung Cancer (NSCLC)
-
Mechanism: RGS20 drives proliferation by inhibiting the Hippo-PKA pathway, enhancing autophagy, and facilitating YAP nuclear translocation .
-
Survival: Elevated RGS20 predicts poorer 5-year survival in lung adenocarcinoma and squamous cell carcinoma .
Mechanistic Insights
RGS20 exerts its oncogenic effects through:
-
PI3K/AKT Pathway Activation: Direct interaction with PI3K p85α subunit enhances AKT signaling, promoting cell survival and metastasis .
-
Cell Cycle Regulation: Modulates cyclin B1, CDC20, and securin to accelerate G1/S transition .
-
Immune Modulation: Associates with infiltrating immune cells (e.g., activated CD4+ T cells) in tumor microenvironments .
Clinical Implications
Product Specs
Target Background
- Silencing of NEAT1 also inhibited tumor growth in vivo. This collective evidence suggests that the NEAT1/miR365/RGS20 axis may represent a novel mechanism or therapeutic target for the treatment of OSCC (Oral Squamous Cell Carcinoma). PMID: 29484420
- Research indicates that Gpr176 (G-protein coupled receptor 176) serves as a SCN-(suprachiasmatic nucleus-)enriched orphan GPCR (G-protein-coupled receptor) that sets the pace of circadian behavior. Notably, a unique cAMP-repressing G-protein subclass, Gz, is essential for the functional activity of Gpr176. [REVIEW] PMID: 28502923
- These findings suggest that the expression of RGS20 may promote metastasis in tumor cells. PMID: 27495875
- Results indicate that elevated expression of regulator of G protein signaling 20 (RGS20) is associated with unfavorable survival outcomes in triple-negative breast cancer (TNBC). PMID: 28237701
- This study provides novel evidence demonstrating that RGSZ1 interacts not only with Galpha(z) but also with Galpha(i), as supported by in vitro binding assays and functional analyses. PMID: 12379657
- NMR study PMID: 14872136
- The primary function of PKCI-1 is to modulate the mu opioid receptor signaling pathway in conjunction with RGSZ1, rather than directly mediating the interaction between Galphaz and RGSZ1. PMID: 17126529
